* **MCV-4** conjugate vaccine (there are two commercial products available: Menactra® and Menveo®) is available for teenagers and young adults, as well as for other high risk individuals, to reduce the risk of **meningococcal meningitis A/C/Y/W-135** types of infection.
* **Men-B** vaccine (there are two commercial products available: Trumenba® & Bexsero®) is available for teenagers and young adults, as well as for other high risk individuals, to reduce the risk of **meningococcal meningitis B** types of infection.
* The CDC-Advisory Committee on Immunization Practices (ACIP) recommends routine administration of a MCV-4 vaccine for all persons aged 11 through 18 years, with a first dose at 11-12 and a second dose at 16-18 years of age. This schedule is expected to protect adolescents and young adults through the highest age-based risk period for active disease.
For those who have not been vaccinated previously, MCV-4 vaccine is recommended for entering college students who will live in on-campus housing. The recommendation, based on evidence for efficacy, safety and cost-effectiveness is available in MMWR Recommendations and Reports (3/22/2013): [www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm)
* Given the seriousness of **meningococcal meningitis B** disease, and the availability of licensed vaccines, ACIP indicates that sufficient evidence exists to encourage conversation and individual clinical decision making regarding use of these vaccines for teenagers and young adults. ACIP references additional information for health care providers and parents at the CDC website:  <http://www.cdc.gov/meningococcal>.
* The CDC-ACIP states that the patient/parents and health care provider may choose, using clinical discretion, to complete a Men-B vaccine series for adolescents and young adults aged 16–23 years to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for Men-B vaccination is 16–18 years. Dosing is based on which of two available vaccines is used. Recommended Immunization Schedules for Children/Teens and for Adults – 2017: [www.cdc.gov/vaccines/schedules/easy-to-read/index.html](http://www.cdc.gov/vaccines/schedules/easy-to-read/index.html)
* Nebraska Law (LB513, 2003) requires that each postsecondary education institution shall provide each newly enrolled student who will reside in on-campus housing (and their parents or guardian), detailed information about meningococcal meningitis disease, and about vaccination available against the disease. A copy of this law is provided in this mailing. Since the type of meningococcal vaccine is not specified, it is the stance of the Immunization Task Force (ITF), that this law applies to all meningococcal meningitis disease for which there are vaccines available. **This currently includes both MCV-4 and Men-B vaccines.**

**More information on Meningococcal Vaccines at:** [**www.cdc.gov/vaccines/vpd/mening/hcp/faqs-adolescent-vaccine.html**](http://www.cdc.gov/vaccines/vpd/mening/hcp/faqs-adolescent-vaccine.html)

**Quadrivalent Meningococcal Conjugate A/C/W/Y vaccines (MCV-4)**\* Menactra®

\* Menveo®

**Serogroup B Meningococcal vaccines (Men-B)**\* Bexsero®

\* Trumenba®

* ***Proprietary names are provided as examples only, with no recommendation intended for specific resources or products.***